Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.57 |
| ▸ | PPIA | P62937 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.52 |
| ▸ | CTSV | O60911 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316766 | 0.90 | CYP19A1 (0.67) | MEN1KMT2AMAPTCYP19A1PPIA | |
| SCHEMBL15509301 | 0.84 | MAPT (1.00) | MEN1KMT2AMAPTCYP19A1PPIA | |
| SCHEMBL15814495 | 0.82 | MEN1 (0.73) | MEN1KMT2AMAPTCYP19A1PPIA | |
| SCHEMBL15814494 | 0.82 | MEN1 (0.73) | MEN1KMT2AMAPTCYP19A1PPIA | |
| SCHEMBL31418722 | 0.81 | MEN1 (0.70) | MEN1KMT2AMAPTCYP19A1PPIA | |
| SCHEMBL371728 | 0.81 | MEN1 (0.70) | MEN1KMT2AMAPTCYP19A1PPIA | |
| SCHEMBL6926436 | 0.80 | MAPT (0.62) | MEN1KMT2AMAPTCYP19A1PPIA | |
| SCHEMBL629596 | 0.79 | CYP19A1 (0.46) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL7825518 | 0.78 | MEN1 (0.67) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL4701157 | 0.77 | MAPT (0.59) | MEN1KMT2AMAPTCYP19A1PPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| CN-101326173-A | Thiadiazoles derivant as anti-diabetes agent | NOVARTIS AG (CH) | 2008-12-17 | — | — | CN | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | MEN1 4331/4885KMT2A 1641/4885MAPT 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.